Keeping Weight Off After Wegovy: What Actually Happens and What Helps

You've stopped Wegovy, here's what your body is doing right now

If you have recently stopped Wegovy, or are thinking about stopping, the scale may already be moving in a direction you did not plan for. That is genuinely disheartening, especially after months of effort. The honest explanation is biological: semaglutide works by mimicking the GLP-1 hormone, slowing gastric emptying and reducing appetite signals in the brain. Remove it, and those signals return to their pre-treatment pattern, usually within days to a couple of weeks, which is part of how long after taking Wegovy it works and how quickly those effects reverse.

The STEP 1 extension study followed participants after they stopped semaglutide 2.4 mg and found that, on average, most of the weight lost during the active treatment phase had returned by one year post-treatment. That data is published in the New England Journal of Medicine and informs how NICE and NHS England describe Wegovy's benefit: it is sustained by continued use, not by a fixed course.

This is why NICE's guidance on semaglutide (Wegovy) recommends it is used within a specialist weight management service with ongoing support, rather than as a time-limited prescription with no follow-up. The therapeutic effect and the ongoing prescription are linked. Keeping weight off after Wegovy, in most cases, means maintaining some form of clinical oversight. Whether stopping Wegovy completely is the right move depends on factors your prescriber is best placed to weigh up.

What lifestyle changes actually do, and what they cannot do alone

It would be misleading to suggest that diet and exercise override the biology above. They do not, for most people. What the evidence does support is that patients who built strong habits during treatment (particularly higher protein intake, resistance-based activity, and consistent meal structure) tend to regain weight more slowly than those who did not. The habits are not a cure; they are a buffer.

Practically, the areas worth focusing on after stopping semaglutide are: keeping dietary protein relatively high (which supports muscle retention and satiety), prioritising resistance or strength-based training over cardio alone, maintaining regular sleep, and managing stress, since cortisol directly influences appetite hormones. None of this is complicated, but all of it requires a level of deliberate structure that most people find easier to maintain when appetite is pharmacologically reduced. Once the medicine stops, the structural habits have to carry more weight.

NHS guidance on semaglutide notes that the medicine should be used alongside a reduced-calorie diet and increased physical activity, and that remains relevant after stopping. The lifestyle component does not disappear in importance; it becomes more, not less, central. Understanding how Wegovy works during active treatment can also help clarify what changes when the medicine is withdrawn.

Continuing treatment, switching medicines, or restarting: the options worth knowing about

For many people, the realistic answer to keeping weight off after Wegovy is not stopping at all, or restarting sooner rather than later. Both options require a prescriber's assessment. UK licensing does not impose a hard maximum duration for Wegovy in private care, and NICE's NHS recommendation of a two-year limit applies specifically to the NHS specialist pathway, not to individually assessed private prescriptions.

Some patients move from semaglutide to tirzepatide (Mounjaro), the dual GIP and GLP-1 receptor agonist, either because they want to explore a different mechanism or because the head-to-head SURMOUNT-5 trial data, published in 2025, showed greater average weight loss with tirzepatide. That is a clinical conversation, not a consumer decision. A prescriber can assess whether a switch is appropriate, what the transition should look like, and what realistic outcomes to expect. You can explore the treatment options available through nume as a starting point.

If cost is a factor in deciding whether to continue treatment, it is worth reading the full picture on Wegovy pricing in the UK, including what legitimate private prescriptions include beyond the medicine itself. Stopping treatment primarily to save money is a decision worth making with full information, not a guess at what the alternatives cost. Whether it is realistic to maintain losses long-term is a question that deserves a direct, evidence-based answer, and one our prescribers discuss regularly with patients who are weighing exactly this decision.

When continuing Wegovy or starting a new course makes clinical sense

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or 27 or above alongside a qualifying weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. If you stopped because of side effects rather than reaching your goals, it is worth discussing whether a lower maintenance dose or a slower titration schedule could change that picture.

A fresh course of semaglutide after a break is pharmacologically straightforward, the medicine re-establishes its effect over the usual titration schedule. Whether that is the right path depends on how much weight has returned, what conditions are present now, and what other treatments have been tried. NHS England's guidance on weight management injections sets out the clinical framework clearly, including the wraparound care expectation. Private prescriptions follow the same licensed criteria but without NHS waiting times or referral thresholds.

If you are at the point of reassessing your options, practical strategies for keeping weight off after semaglutide covers the day-to-day approach in more detail. And if you want a prescriber's view on your specific situation, starting a free consultation is the quickest way to get one.